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Abstract
Introduction: Pulmonary embolism remains one of the leading causes of cardiovascular mortality. The standard
treatment for pulmonary embolism is anticoagulant therapy using low molecular weight heparin, fondaparinux and
a vitamin K antagonist, but a recent clinical trial showed that rivaroxaban, an oral factor Xa inhibitor, was as effective as
standard therapy for the initial and long-term treatment of pulmonary embolism and had less bleeding complications.
Case presentation: The present report describes the case of an 80-year-old white man with an intermediate to low
early mortality risk of pulmonary embolism. He was successfully treated with rivaroxaban (administered orally as
monotherapy), demonstrating rapid benefit without any adverse events.
Conclusion: Rivaroxaban, particularly in the acute phase of pulmonary embolism, may be considered an effective and
safe therapeutic choice even in elderly patients, a population less represented in clinical trials.
Keywords: Anticoagulant, Case report, Elderly, Mortality risk, Pulmonary embolism, Rivaroxaban
Introduction
The elements that constitute venous thromboembolism
(VTE) are deep vein thrombosis (DVT) and pulmonary
embolism (PE). VTE is the third most frequent cardio-
vascular disease, with an overall annual prevalence of
100 to 200 cases per 100,000 inhabitants [1, 2].
PE is defined as the blockage of the main pulmonary
artery or its branches by substances that have travelled
through the bloodstream, most commonly resulting
from DVT. It is difficult to assess its epidemiology be-
cause it can remain asymptomatic for a long period of
time, or its diagnosis may be an incidental finding [2].
PE is responsible for the mortality, morbidity, and
hospitalization in a significant number of patients in
Europe [3]. The main clinical characteristics of patients
with suspected PE are dyspnea, chest pain, fever,
hemoptysis, syncope and signs of DVT. In some cases,
the first presentation of PE may be sudden death [3, 4].
Diagnosis is based on clinical findings in combination
with laboratory tests (such as the D-dimer test) and
imaging studies, usually a computed tomographic (CT)
pulmonary angiography.
The standard therapy for patients with acute PE is low
molecular weight heparin (LMWH), fondaparinux over-
lapped with and then followed by vitamin K antagonists
(VKA); the VKAs are dose-adjusted to keep an inter-
national normalized ratio (INR) between 2.0 and 3.0.
This regimen is effective but complex. In the EINSTEIN
PE clinical trial rivaroxaban, a direct and reversible inhibi-
tor of factor Xa that can be administered orally, demon-
strated non-inferiority versus standard treatment in terms
of primary outcome (recurrent VTE) in patients with
symptomatic PE with objective confirmation, with or
without symptomatic DVT. Furthermore, major bleeding
was reduced in the rivaroxaban group compared to the
standard therapy group [5].
Based on these promising results, we decided to treat
an elderly patient with PE without hemodynamic com-
promise with rivaroxaban.
Case presentation
An 80-year-old white man was admitted to our emer-
gency department (DEA) presenting with dyspnea; this
symptom appeared 2 weeks before and worsened a few
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days prior to hospital admission. He did not present
other symptoms or signs; in particular he did not report
thoracic pain or unilateral extremity swelling. He had no
previous episodes of VTE, major trauma, immobilization
or any other risk factors, such as obesity, cancer or fam-
ily history suggestive of inherited thrombophilia.
His main predisposing factor for VTE was advanced
age. His medical history included arterial hypertension,
previous left varicectomy and right saphenectomy. On
examination, his systolic blood pressure was 130/80
mmHg and pulse rate was 100 beats per minute. His re-
spiratory rate was 24 breaths/minute and arterial oxy-
hemoglobin saturation was 90 % at room air. His oral
temperature was 36 °C and his mental status was pre-
served. Chest auscultation did not reveal pathological
lung sounds. An electrocardiogram (ECG) showed a nor-
mal sinus rhythm with inversion of T waves in leads V3
to V6 (Fig. 1a) not detected in previous recordings
(Fig. 1b). Arterial blood gas analysis revealed a mild hyp-
oxemia with respiratory alkalosis. His chest X-ray was
normal. No supplemental oxygen was administered.
Laboratory findings on admission revealed a high serum
D-dimer level (6987 ng/L), elevated high-sensitivity car-
diac troponin concentration (137 ng/l) and increased
serum level of pro-B-type natriuretic peptide (pro-BNP;
6166 ng/L), while renal (creatinine 1.53 mg/dl and glom-
erular filtration rate 43 ml/minute/1.73m2) and liver
function were normal. The focused assessment with son-
ography for trauma (FAST) scan performed in DEA
showed a moderate right ventricular (RV) dilation and
hypokinesia with flattening of his interventricular septum
and dilated inferior vena cava.
Together, these findings led to the suspicion of PE,
subsequently confirmed by a CT pulmonary angiography
(Fig. 2).
According to the simplified PE Severity Index (sPESI;
Table 1), an extensively validated prognostic tool for pre-
dicting death and adverse outcome events in patients
with PE, our patient had a score of 0. This data, in com-
bination with the hemodynamic status of our patient,
signs of RV dysfunction and cardiac laboratory bio-
markers, allowed us to classify our patient as having an
intermediate to low risk of early mortality.
Given the diagnosis of bilateral PE and encouraged by
the results of the EINSTEIN PE trial [5], we decided to
start therapy with rivaroxaban (15 mg, twice daily). In the
following days the patient showed a progressive improve-
ment of clinical status and laboratory tests. His troponin
levels decreased from 905 ng/L on day 2 to 26 ng/L on day
4, pro-BNP from 6166 ng/L on day 1 to 543 ng/L on day 4
and D-dimer from 6987 ng/L to 1385 ng/L (Table 2). Fur-
thermore, his partial pressure of oxygen (pO2) increased
from 68.9 to 136.4 mmHg and the following parameters
remained in the normal range; pH, partial pressure of
Fig. 1 Electrocardiogram on admission and previous electrocardiogram without pathological features. a Electrocardiogram on admission: sinus
rhythm with inversion of T waves in anterior and lateral leads. b Previous electrocardiogram without pathological features
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carbon dioxide (pCO2) and fraction of inspired oxygen
(FiO2). Supplemental oxygen was not administered.
Five days after starting therapy, we performed another
echocardiography showing a normalized RV function:
ejection fraction (EF) of 55 %, systolic pulmonary artery
pressure (PAPs) of 30 mmHg, and tricuspid annular
plane systolic excursion (TAPSE) of 26 mm.
Seven days after starting treatment, the patient under-
went a CT pulmonary angiography that revealed a sig-
nificant improvement of filling defects in the lower lobes
(Fig. 3).
Discussion
PE is a potentially life-threatening medical emergency that
requires urgent intervention. Occlusion of the pulmonary
arterial bed can lead to a potentially reversible RV failure.
The diagnosis of PE can be missed because of nonspecific
clinical presentation. However, early diagnosis is funda-
mental, since immediate treatment is highly effective [1, 2].
There is an extensive range of patient-related and
setting-related risk factors. PE can be ‘provoked’ in the
presence of temporary or reversible risk factors (such as
surgery, trauma and immobilization) and ‘unprovoked’
in their absence. PE may also occur in the absence of
any known risk factor. Patients older than 40 years are
at increased risk compared with younger patients and
the risk approximately doubles with each subsequent
decade [6].
In the present case we describe a patient who pre-
sented with dyspnea without any other symptom or risk
factor for PE, except that of advanced age. A physical
examination and investigations did not support the pos-
sible existence of any other cause of dyspnea and led to
the suspicion of PE. According to current guidelines [6],
given the hemodynamic stability and low PE clinical
probability of the patient, we first assessed serum D-
dimer levels and then we performed a CT pulmonary
Fig. 2 Computed tomographic pulmonary angiography on admission: multiple filling defects within the pulmonary trunk and the right
pulmonary artery. Left pulmonary artery presents similar features. These computed tomography findings are suggestive of pulmonary
thromboembolism (Miller index >17)
Table 1 Simplified Pulmonary Embolism Severity Index score
Variable Simplified Pulmonary Embolism
Severity Index score
Age >80 years 1
History of cancer 1
Chronic cardiopulmonary disease* 1
Pulse ≥110 beats/minute 1
SBP <100 mmHg 1
Arterial oxyhemoglobin saturation level
<90 %
1
SBP systolic blood pressure. *Combined variable of history of heart failure and
history of chronic lung disease
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angiography. This imaging test supported the diagnosis
of bilateral PE. Echocardiography showed a RV dysfunc-
tion with significant overload. The combination of clin-
ical findings with imaging and laboratory tests allows
stratification of the early mortality risk (understood as
in-hospital or 30-day mortality). Our patient, having a
sPESI of 0 but both positivity for signs of RV dysfunc-
tion and cardiac laboratory biomarkers, was classified as
having an intermediate to low early mortality risk.
The sPESI score [7–9] is used by many emergency
physicians and acute care internists to stratify the risk of
patients with PE in order to determine the most appro-
priate management approach, including suitability for
out-patient care. The score predicts 30-day mortality fol-
lowing PE based on factors such as age, blood pressure,
heart rate, oxygen saturation and the presence of chronic
cardiopulmonary disease or cancer.
For half a century, the standard therapy for PE has
been the administration of parental anticoagulant over-
lapped with and then followed by a VKA [10]. This regi-
men has been shown to be extremely effective but with
several limitations: requirement for laboratory monitor-
ing and regular dose adjustments, need for injection,
narrow therapeutic window and interactions with food
and other drugs. Novel oral anticoagulants overcome the
limitations of this standard therapy.
Rivaroxaban is a direct and reversible inhibitor of fac-
tor Xa that can be administered orally [11, 12]. It offers
a simple single-drug approach for initial intensive treat-
ment with a high dose (15 mg twice a day) administered
for 3 weeks followed by administration of a standard
dose (20 mg once a day). Findings from the recent EIN-
STEIN PE trial indicate that rivaroxaban was non-
inferior compared to standard therapy (2.1 % events in
Table 2 Laboratory findings on admission (27 January 2014) and the next 3 days
Day 1 2 3 4
Time (hour) 16:00 08:00 18:00 08:00 18:00 08:00
Troponin T >50 ng/L 137 ng/L 90.5 ng/L 67 ng/L 69 ng/L 60 ng/L 26 ng/L
Pro-BNP <1800 ng/L 6166 ng/L 5495 ng/L 3180 ng/L 1496 ng/L 926 ng/L 543 ng/L
D-dimer <100 ng/L 6987 ng/L 5688 ng/L 3224 ng/L NA NA 1385 ng/L
After admission, the patient started treatment with rivaroxaban (15 mg twice a day). NA data not available, Pro-BNP pro-B-type natriuretic peptide
Fig. 3 Computed tomographic pulmonary angiography at the 7-day follow-up: partial reperfusion of lower lobe pulmonary arteries. The other
computed tomography findings appear unchanged
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the rivaroxaban group versus 1.8 % in the standard ther-
apy group; hazard ratio 1.12; 95 % confidence interval,
CI, 0.75 to 1.68) and no increase in adverse events when
compared with standard treatment (LMWH with VKA)
[5]. In particular, the safety profile was attractive because
major bleeding was observed in 26 patients (1.1 %) in
the rivaroxaban group and 52 patients (2.2 %) in the
standard therapy group (hazard ratio 0.49; 95 % CI 0.31
to 0.79; P=0.003).
This paper presents some similarities with respect to
this clinical trial but the age of our patient was not com-
parable (80 years versus a mean age of 57.9±7.3 years in
EINSTEIN PE). Despite the older age of our patient, we
felt confident in using rivaroxaban instead of standard
therapy. In fact, treatment with rivaroxaban led to rapid
improvement and normalization (after 3 days) of PE-
related early mortality risk markers.
Conclusions
In summary, this is the first case report showing that ini-
tial intensive treatment with rivaroxaban in an elderly
patient resulted in a rapid clinical improvement and
normalization of PE-related early mortality risk parame-
ters. Furthermore, no adverse events were noted. This
case suggests that rivaroxaban can be considered an ef-
fective alternative to standard therapy with LMWH and
oral VKA for elderly patients with a hemodynamically
stable PE.
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